Summary
Liposomes expressing external antibody specific for Candida albicans and encapsulating amphotericin B were developed and characterized in this study. Antibody was first modified by the covalent attachment of palmitic acid residues. Liposomes were produced by reverse-phase evaporation and modified antibody was incorporated into these liposomes via the hydrophobic interaction between the palmitic acid and the phospholipids composing the liposomes. The liposomes were characterized as to the amount of amphotericin B by spectroscopy and for the presence of antibody by protein analysis and secondary immunolabeling by fluorescent and electron microscopic methods. Immunogold labeling showed that the antibody was being expressed externally on the liposomes in the electron microscopic studies and the specificity of these liposomes for C. albicans was observed by secondary immunofluorescence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bendayan M. Protein A-gold electron microscopic immunocytochemistry: Methods, applications, and limitations. J Electron Microsc Tech 1984; 1:243–270.
Difco Laboratories. Bacto Candida albicans antisera. In: Difco Manual. 10th Edition. Difco Laboratories Inc, Detroit, 1984; 196–198.
Feld R, Bodey GP, Rodriguez V, Luna M. Cause of death in patients with malignant lymphoma. Am J Med Sci 1974; 268:97–106.
Hashimoto Y, Endoh H, Minoran S. Chemical methods for the modification of liposomes with proteins or antibodies. In: Gregoriadis G (ed). Liposome technology, Vol. III. Targeted drug delivery and biological interaction. Boca Raton, Florida: CRC Press, 1984; 41–50.
Heath TD, Montgomery JA, Piper JR, Papahadjopoulos D. Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-γ-aspartate. Proc Natl Acad Sci USA 1983; 80:1377–1381.
Hopfer RL, Mills K, Mehta R, Lopez-Berestein G, Fainstein V, Juliano RL. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 1984; 25:387–389.
Huang L, Huang A, Kennel SJ. Coupling of antibodies with liposomes. In: Gregoriadis G (ed). Liposome technology, Vol. III. Targeted drug delivery and biological interaction. Boca Raton, Florida: CRC Press, 1984; 51–62.
Juliano RL, Lopez-Berestein G, Hopfer R, Mehta R, Mehta K, Mills K. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann NY Acad Sci 1985; 446:390–402.
Juliano R, Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Kasi L. Pharmacokinetic and therapeutic consequences of liposomal drug delivery: Fluorideoxyuridine and amphotericin B as examples. Biol Cell 1983; 47:39–46.
Lapidot Y, Rappoport S, Wolman Y. Use of esters of N-hydrosuccinimide in the synthesis of N-acylamino acids. J Lipid Res 1967; 8:142–145.
Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J Infect Dis 1985; 151:704–710.
Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 1984; 25:366–367.
Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulate amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984; 150:278–283.
Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983; 147:939–945.
Lowry OH, Rosebrough NJ, Fall AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265–275.
Mehta RT, Lopez-Berestein G, Hopfer RL, Mehta K, White RA, Juliano RL. Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother 1985; 28:511–513.
Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984; 770:230–234.
Shen D, Huang A, Huang L. An improved method for covalent attachment of antibodies to liposomes. Biochim Biophys Acta 1982; 689:31–37.
Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA. Hepatosplenic fungal infections: CT and pathological evaluation after treatment with liposomal amphotericin B. Radiology 1986; 159:349–353.
Skipski VP, Barclay M. Thin-layer chromatography of lipids. In: Lowenstein JM (ed). Methods in enzymology, Vol. XIV. Lipids. New York: Academic Press, 1969; 530–597.
Sundstrom PM, Kenny OE. Characterization of antigens specific to the surface of germ tubes of Candida albicans by immunofluorescence. Infect Immun 1984; 43:850–855.
Szoka FC, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated Amphotericin B. Antimicrob Agents Chemother 1987; 31:421–429.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hospenthal, D.R., Rogers, A.L. & Mills, G.L. Development of amphotericin B liposomes bearing antibody specific to Candida albicans . Mycopathologia 101, 37–45 (1988). https://doi.org/10.1007/BF00455667
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00455667